Debug Stats | ### Total Build Time: 46 ms 50.332 KB CONCEPT_NAME gt=0 Completed: 0 ms rowSize= 326 bytesCONCEPT_SOLR_HIT_STATS gt=0 Completed: 0 ms rowSize= 14 bytesCONCEPT_DEFINITION gt=0 Completed: 0 ms rowSize= 322 bytes- Skipping details on:
CONCEPT_SYNONYM gt=NONE 0 Completed: 0 ms rowSize= 0 bytes - Skipping details on:
CONCEPT_TEXT gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_SEMANTIC_TYPE gt=0 Completed: 0 ms rowSize= 187 bytes- Skipping details on:
CONCEPT_NAMESPACE gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_PARENTS gt=0 Completed: 0 ms rowSize= 984 bytesCONCEPT_CHILDREN gt=5 ms Completed: 5 ms rowSize= 1.810 KBCONCEPT_ANCESTRAL_ROOTS gt=0 Completed: 0 ms rowSize= 2.755 KBCONCEPT_RELATIONSHIPS gt=26 ms Completed: 26 ms rowSize= 14.374 KBCONCEPT_GENES gt=14 ms Completed: 14 ms rowSize= 28.441 KBCONCEPT_XREFS gt=1 ms Completed: 1 ms rowSize= 1.148 KBCONCEPT_ANCILLARY gt=0 Completed: 0 ms rowSize= 14 bytes- Reload Stats
|
Genes (21)
Species: human : 20 mouse : 1 | |
Mouse | TNFRSF11B | 4982 | tumor necrosis factor receptor superfamily, member 11b | For example, the expression of various metalloproteinases (MMPs) in PC3 bone tumors was inhibited by genistein treatment, whereas osteoprotegerin was upregulated. Osteoprotegerin treatment decreased the number of osteoclasts by 90% (p < 0.0007) at sites of tumor in a dose-dependent manner and decreased bone tumor area by greater than 90% (p < 0.003). Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice. | Human | C1QTNF3 | 114899 | C1q and tumor necrosis factor related protein 3 | Therefore, a human bone tumor cDNA panel was investigated and a strong CORS-26 mRNA expression was found in osteosarcoma, chondroblastoma and giant cell tumor. | Human | TNFRSF11A | 8792 | tumor necrosis factor receptor superfamily, member 11a, NFKB activator | RANKL/RANK have roles in bone-associated tumors (review) This study is the first report of functional RANK expression in human osteosarcoma cells: this strengthens the involvement of the RANK-RANKL-OPG axis in primary bone tumour biology and identifies novel therapeutic approaches targeting RANK-positive osteosarcoma. The members of the OPG/RANK/RANKL (osteoprotegerin/receptor activator of nuclear factor kappaB/RANK ligand) triad are involved in various osteolytic pathologies such as bone tumors. | Human | TNFSF11 | 8600 | tumor necrosis factor (ligand) superfamily, member 11 | RANKL/RANK have roles in bone-associated tumors (review) | Human | TGFB2 | 7042 | transforming growth factor, beta 2 | INFERRED, Score=800, UMLKSK CUI: C0005967 | Human | SYP | 6855 | synaptophysin | INFERRED, Score=800, UMLKSK CUI: C0005967 | Human | TNFRSF11B | 4982 | tumor necrosis factor receptor superfamily, member 11b | In the present study we used a model in which human LNCaP prostate cancer cells that give rise to osteoblastic bone tumors were injected directly into the intramedullary space of human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice to investigate whether the new bone-resorption inhibitor osteoprotegerin/OCIF would inhibit the development of new bone tumors and the progression of established osteoblastic bone tumors. A comparison with other lytic and nonlytic tumors of bone showed that GCT express more ODF and TRAIL mRNA relative to OPG mRNA. We recently showed that the stromal cells of osteolytic giant cell tumors (GCT) of bone express high levels of mRNA encoding RANKL, relative to mRNA for the RANKL antagonist, OPG, compared with the expression patterns of other lytic and nonlytic bone tumors. | Human | NME1 | 4830 | NME/NM23 nucleoside diphosphate kinase 1 | OBJECTIVE: To explore the correlation between nm23-H1 gene and malignant and semi-malignant bone tumors. Bone-metastatic tumors have been characterized by decreased NM23 and increased c-met and p53 expressions. These results showed that, in contrast to reports on breast cancer and experimental models, nm23 protein expression in human bone tumors may be associated with malignant potentiality, except in cases of osteosarcoma. These results showed that, in contrast to reports on breast cancer and experimental models, nm23 protein expression in human bone tumors may be associated with malignant potentiality, except in cases of osteosarcoma. [Association of nm23-H1 with orthopedic oncological conditions] OBJECTIVE: To explore the correlation between nm23-H1 gene and malignant and semi-malignant bone tumors. | Human | NF2 | 4771 | neurofibromin 2 (merlin) | INFERRED, Score=800, UMLKSK CUI: C0005967 | Human | NF1 | 4763 | neurofibromin 1 | INFERRED, Score=800, UMLKSK CUI: C0005967 | Human | MTNR1A | 4543 | melatonin receptor 1A | on the abundant expression of MT1-mRNA in human bone tumors and osteosarcoma cells lines suggest an important role for MT1 in bone pathology | Human | CD99 | 4267 | CD99 molecule | INFERRED, Score=800, UMLKSK CUI: C0005967 | Human | KRT1 | 3848 | keratin 1 | INFERRED, Score=800, UMLKSK CUI: C0005967 | Human | FAU | 2197 | Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) ubiquitously expressed | This high incidence of creating retropseudogenes in these 90Sr-induced bone tumours may contribute to the mechanism by which FBR-MuSV, originally isolated from such tumours, acquired the fau gene in its reverse orientation. | Human | EXT3 | 2133 | exostoses (multiple) 3 | Two homologous genes, EXT1 and EXT2, responsible for the development of benign multiple cartilagenous bone tumors (exostoses) on the long bones, have been identified in the past 2 years. | Human | EXT2 | 2132 | exostosin glycosyltransferase 2 | Two homologous genes, EXT1 and EXT2, responsible for the development of benign multiple cartilagenous bone tumors (exostoses) on the long bones, have been identified in the past 2 years. | Human | TPP1 | 1200 | tripeptidyl peptidase I | Tripeptidyl peptidase I (EC 3.4.14.9), which cleaves tripeptides from the N-terminus of synthetic substrates, has been purified from human osteoclastomas (a bone tumor containing large numbers of normal osteoclasts). | Human | CDH13 | 1012 | cadherin 13 | Although functional studies are needed to better define the role of CDH13 and CAV1 in the malignant behavior of osteosarcoma cells, the data presented here provide an aid to understanding the biological functions of L/B/K ALP in bone tumors. | Human | CAV1 | 857 | caveolin 1, caveolae protein, 22kDa | Although functional studies are needed to better define the role of CDH13 and CAV1 in the malignant behavior of osteosarcoma cells, the data presented here provide an aid to understanding the biological functions of L/B/K ALP in bone tumors. | Human | BMPR2 | 659 | bone morphogenetic protein receptor, type II (serine/threonine kinase) | Previous data have shown that the overexpression of the BMPR-II was related to poor prognosis in malignant and metastatic bone tumors. | Human | CEACAM1 | 634 | carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) | These observations indicate that BGP synthesis is a late event in osteoblastic development and that antibodies generated against the propeptide sequence are a potentially powerful tool in the analysis of bone tumors and evaluation of osteoblastic differentiation. |
|